Discover

PCRX
Pacira BioSciences, Inc.
25.03
2 x 18.30
2 x 31.80
bid
ask
-
0.34
1.34%
2 @ 04:00 PM
25.44 +0.41 (1.64%)
Ytd-3.28%
1y7.66%
24.59
day range
25.85
18.80
52 week range
27.64
Open25.75Prev Close25.37Low24.59High25.85Mkt Cap984.88M
Vol543.14KAvg Vol528.55KEPS0.13P/E192.54Forward P/E6.87
Beta0.20Short Ratio11.24Inst. Own118.81%DividendN/ADiv YieldN/A
Ex Div DateN/AEarning04-3050-d Avg23.69200-d Avg23.411yr Est29.00

PCRX News

Pacira to Divest iovera Business to Zimmer Biomet in Up To $140M Deal
zacks.com
Pacira to Divest iovera Business to Zimmer Biomet in Up To $140M Deal

PCRX is set to sell its iovera franchise to ZBH in a deal worth up to $140M as it sharpens focus on

benzinga.com
HC Wainwright & Co. Reiterates Buy on Pacira BioSciences, Maintains $38 Price Target

HC Wainwright & Co. analyst Douglas Tsao reiterates Pacira BioSciences (NASDAQ:PCRX) with a B

benzinga.com
Pacira BioSciences Says UnitedHealthcare Now Provides Separate Reimbursement For EXPAREL Across Outp

-- Expands Patient Access to Non-Opioid Postsurgical Pain Management Across Outpatient Settings -- B

Pacira BioSciences Announces UnitedHealthcare Now Provides Separate Reimbursement for EXPAREL®
globenewswire.com
Pacira BioSciences Announces UnitedHealthcare Now Provides Separate Reimbursement for EXPAREL®

-- Expands Patient Access to Non-Opioid Postsurgical Pain Management  Across Outpatient Settings -- 

benzinga.com
Pacira BioSciences Divests Iovera To Zimmer Biomet For Up To $140M

Pacira BioSciences, Inc. (Nasdaq: PCRX), the industry leader in its commitment to deliver innovative

Pacira BioSciences Announces Agreement to Divest its iovera° Business to Zimmer Biomet
globenewswire.com
Pacira BioSciences Announces Agreement to Divest its iovera° Business to Zimmer Biomet

-- Pacira to receive up to $140 million with $70 million upfront and up to an additional $70 million

benzinga.com
Pacira BioSciences Announces Findings From Real-World Study Evaluating Outcomes Associated With Use

Findings presented at ISPOR 2026 showed lower opioid consumption, reduced healthcare costs, and fewe

benzinga.com
RBC Capital Maintains Sector Perform on Pacira BioSciences, Raises Price Target to $24

RBC Capital analyst Douglas Miehm maintains Pacira BioSciences (NASDAQ:PCRX) with a Sector Perfor

benzinga.com
Needham Maintains Buy on Pacira BioSciences, Raises Price Target to $32

Needham analyst Serge Belanger maintains Pacira BioSciences (NASDAQ:PCRX) with a Buy and raises t

Pacira BioSciences Q1 2026 Earnings Call Transcript
benzinga.com
Pacira BioSciences Q1 2026 Earnings Call Transcript

benzinga.com
Pacira BioSciences Affirms FY2026 Sales Guidance of $745.000M-$770.000M vs $759.317M Est

Pacira BioSciences, Inc.___________________________ Summary of 2026 Financial Guidance(dollars in mi

benzinga.com
Pacira BioSciences Q1 Adj. EPS $0.60 Beats $0.56 Estimate, Sales $177.376M Beat $173.325M Estimate

Pacira BioSciences (NASDAQ:PCRX) reported quarterly earnings of $0.60 per share which beat the analy

Earnings Scheduled For April 30, 2026
benzinga.com
Earnings Scheduled For April 30, 2026

benzinga.com
Pacira BioSciences Announces Findings From A Study Evaluating The Clinical And Economic Impact Of Ex

The data were presented at the Annual Regional Anesthesiology and Acute Pain Medicine Meeting, hoste

12 Health Care Stocks Moving In Thursday's After-Market Session
benzinga.com
12 Health Care Stocks Moving In Thursday's After-Market Session

benzinga.com
Pacira BioSciences Presents Data From Three Studies Supporting Economic Value Of EXPAREL In Total Hi

Pacira BioSciences, Inc. (NASDAQ: PCRX), the industry leader in its commitment to deliver innovative

benzinga.com
Barclays Maintains Equal-Weight on Pacira BioSciences, Lowers Price Target to $25

Barclays analyst Glen Santangelo maintains Pacira BioSciences (NASDAQ:PCRX) with a Equal-Weight a

Absci, DigitalOcean And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session
benzinga.com
Absci, DigitalOcean And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session

U.S. stock futures rise, Absci falls pre-market on worse-than-expected sales. Other stocks declining

Pacira Faces Board Fight As Activist Investor Criticizes CEO Pay, Missed Earnings
benzinga.com
Pacira Faces Board Fight As Activist Investor Criticizes CEO Pay, Missed Earnings

Activist investor DOMA nominates three directors to Pacira's board, citing weak oversight, misse

benzinga.com
Pacira BioSciences Issues Statement In Response To DOMA's Nomination Of Director Candidates; Reaffir

Pacira BioSciences, Inc. (NASDAQ:PCRX), the industry leader in its commitment to deliver innovative,

benzinga.com
DOMA Perpetual Asserts Pacira BioSciences CEO Frank Lee Should Be Replaced Immediately; Urges Board

Pacira's Stock is Down 56% Over the Last Decade and Down 68% Over the Last 5 Yearsi; Under the L

benzinga.com
Pacira BioSciences Presents Real-World Evidence From Innovations In Genicular Outcomes Registry At A

-- Studies highlight the clinical effectiveness of EXPAREL for total knee arthroplasty and long-term

benzinga.com
Pacira BioSciences Sees FY2026 Sales $745.000M-$770.000M vs $790.214M Est.

Pacira BioSciences (NASDAQ:PCRX) sees FY2026 sales of $745.000 million-$770.000 million vs $790.214

Pacira BioSciences Q4 Earnings Assessment
benzinga.com
Pacira BioSciences Q4 Earnings Assessment

benzinga.com
Pacira BioSciences Q4 Adj. EPS $0.57 Misses $0.90 Estimate, Sales $196.873M Miss $200.424M Estimate.

Pacira BioSciences (NASDAQ:PCRX) reported quarterly earnings of $0.57 per share which missed the ana

Earnings Scheduled For February 26, 2026
benzinga.com
Earnings Scheduled For February 26, 2026

benzinga.com
Pacira BioSciences Enters Into Agreement With LG Chem To Expand Access To Opioid-Sparing Postsurgica

-- LG Chem becomes exclusive distributor of EXPAREL -- – Partnership expands patient access to opioi

Crude Oil Rises Sharply; US Consumer Sentiment Edges Higher In January
benzinga.com
Crude Oil Rises Sharply; US Consumer Sentiment Edges Higher In January

12 Health Care Stocks Moving In Friday's Pre-Market Session
benzinga.com
12 Health Care Stocks Moving In Friday's Pre-Market Session

What Analysts Are Saying About Pacira BioSciences Stock
benzinga.com
What Analysts Are Saying About Pacira BioSciences Stock

benzinga.com
HC Wainwright & Co. Reiterates Buy on Pacira BioSciences, Maintains $38 Price Target

HC Wainwright & Co. analyst Douglas Tsao reiterates Pacira BioSciences (NASDAQ:PCRX) with a B

benzinga.com
Needham Maintains Buy on Pacira BioSciences, Maintains $30 Price Target

Needham analyst Serge Belanger maintains Pacira BioSciences (NASDAQ:PCRX) with a Buy and maintain

benzinga.com
Barclays Initiates Coverage On Pacira BioSciences with Equal-Weight Rating, Announces Price Target o

Barclays analyst Glen Santangelo initiates coverage on Pacira BioSciences (NASDAQ:PCRX) with a Eq

benzinga.com
Pacira BioSciences Announces Results From Randomized 30-Patient Pilot Study Evaluating Iovera° Cryon

-- New data published in Pain Physician shows significant improvement in functional outcomes with io

benzinga.com
Pacira Biosciences Files Patent Infringement Lawsuit In U.S. District Court Against The WhiteOak Gro

Pacira BioSciences, Inc. (NASDAQ:PCRX), the industry leader in its commitment to deliver innovative,

benzinga.com
HC Wainwright & Co. Assumes Pacira BioSciences at Buy, Announces Price Target of $38

HC Wainwright & Co. analyst Douglas Tsao assumes Pacira BioSciences (NASDAQ:PCRX) with a Buy

benzinga.com
Truist Securities Maintains Buy on Pacira BioSciences, Lowers Price Target to $28

Truist Securities analyst Les Sulewski maintains Pacira BioSciences (NASDAQ:PCRX) with a Buy and

benzinga.com
Pacira BioSciences Lowers FY2025 Sales Guidance from $730.000M-$750.000M to $725.000M-$735.000M vs $

Pacira BioSciences (NASDAQ:PCRX) lowers FY2025 sales outlook from $730.000 million-$750.000 million

benzinga.com
Pacira BioSciences Q3 Adj. EPS $0.70 Beats $0.65 Estimate, Sales $179.516M Miss $182.552M Estimate

Pacira BioSciences (NASDAQ:PCRX) reported quarterly earnings of $0.70 per share which beat the analy

Earnings Scheduled For November 6, 2025
benzinga.com
Earnings Scheduled For November 6, 2025

benzinga.com
Pacira BioSciences Completes Patient Enrollment For Part A Of Its Phase 2 Ascend Trial Evaluating PC

Pacira BioSciences, Inc. (NASDAQ: PCRX), the industry leader in its commitment to deliver innovative

benzinga.com
Pacira Biosciences Inks Exclusive Worldwide License And Collaboration Agreement With AmacaThera For

Pacira BioSciences, Inc. (NASDAQ:PCRX), the industry leader in its commitment to deliver innovative,

benzinga.com
Pacira BioSciences To Present Real-World Evidence Evaluating Clinical Effectiveness And Economic Ben

-- Findings Presented at AMCP Nexus 2025 Annual Meeting --BRISBANE, Calif., Oct. 23, 2025 (GLOBE NEW

benzinga.com
Pacira BioSciences Receives Paragraph IV Notice Letter For EXPAREL From WhiteOak Group, Subsidiary o

Pacira BioSciences, Inc. (NASDAQ:PCRX), the industry leader in its commitment to deliver innovative,

PACCAR Posts Downbeat Earnings, Joins Neuphoria Therapeutics, Citius Pharmaceuticals And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session
benzinga.com
PACCAR Posts Downbeat Earnings, Joins Neuphoria Therapeutics, Citius Pharmaceuticals And Other Big S

benzinga.com
Pacira BioSciences Narrows FY2025 Sales Guidance from $725.000M-$765.000M to $730.000M-$750.000M vs

Pacira BioSciences (NASDAQ:PCRX) narrows FY2025 sales outlook from $725.000 million-$765.000 million

benzinga.com
Pacira BioSciences Q2 Adj. EPS $0.74 Beats $0.68 Estimate, Sales $181.099M Miss $183.330M Estimate

Pacira BioSciences (NASDAQ:PCRX) reported quarterly earnings of $0.74 per share which beat the analy

benzinga.com
Earnings Scheduled For August 5, 2025

benzinga.com
Insights Ahead: Pacira BioSciences's Quarterly Earnings

benzinga.com
Pacira BioSciences Collaborates With Johnson & Johnson MedTech To Expand Market Reach Of ZILRETTA, L

Partnership expected to advance 5x30 strategy by increasing ZILRETTA sales calls and extensively exp